Background: No independent comparisons, with midterm follow-up, of standard arteriovenous grafts (SAVGs) and immediate-access arteriovenous grafts (IAAVGs) exist. The goal of this study was to compare "real-world" performance of SAVGs and IAAVGs.
For decades, arteriovenous fistulas (AVFs) have been the favored access modality for patients reliant on hemodialysis (HD). This trend was bolstered in 2006 by the release of the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative guidelines, with companion publication of synonymous clinical practice guidelines by the Society for Vascular Surgery.
1,2 Arteriovenous grafts (AVGs) are considered a second-line access modality in comparison to AVFs. This is largely due to the AVG's inferior patency rates and frequent reinterventions.
Tunneled dialysis catheters (TDCs) serve as a "last-resort" means of access yet account for >75% of initial HD access in the United States. 3 AVGs have a growing acceptance as an incident access modality in patients with inadequate superficial venous anatomy or limited life expectancy. 4, 5 For all patients, regardless of their access type, if they are already HD dependent, any period between access creation and successful cannulation will require a TDC, with its associated risks: induction of central venous stenosis and infection.
Early cannulation of standard AVGs (SAVGs), using small-bore needles, diligent antisepsis, and attentive pressure for hemostasis, dates to the 1990s, with reports of improved postcannulation hemostasis with some of the first iterations of immediate-access AVGs (IAAVGs). 6 These IAAVGs have become increasingly available in the last decade. Numerous industry-driven noncomparative studies have shown patency rates comparable to those in published literature for SAVGs but with the claimed additional benefit of shorter interval periods of catheter dependence. 7 Although encouraging, the short-term results of these prospective, single-arm clinical trials of the current, commercially available IAAVGs do not represent independent experience with 12-to 18-month outcomes of these grafts' performance in the heterogeneous treatment setting of the United States. Furthermore, these studies do not offer a "samecenter"' comparison of IAAVGs with SAVGs in a practical setting.
The goal of this project was to provide "real-world" comparison of performance and midterm outcomes of IAAVGs and SAVGs at two major tertiary centers in the United States.
METHODS
This study is a two-institution retrospective review of 210 consecutive attempts at AVG implantation between November 2014 and April 2016. At the two participating centers, SAVGs were procured from Gore (W. L. Gore & Associates, Flagstaff, Ariz). At these centers, two types of IAAVG have been incorporated into clinical practice: Acuseal (Gore) and Flixene (Atrium Medical Corporation, Hudson, NH). All grafts are commercially available, and none of the procedures were performed as part of an industry-funded trial.
After Institutional Review Board approval was obtained for waived informed consent at both institutions, consecutive patients who underwent placement of an AVG for HD access between November 2014 and April 2016 were retrospectively identified from the electronic medical record and the Vascular Quality Initiative database. Only grafts with direct arterial inflow and venous outflow were included for analysis. Interposition graft placements were excluded from analysis. Patients were divided into two groups based on the type of graft implanted (SAVG and IAAVG). Patients' comorbidities, graft configuration, operative characteristics, and subsequent follow-up were collected and analyzed with respect to primary and secondary patency. Additional outcomes included graft-related complications, time to first cannulation, time to tunneled catheter removal, catheter-related complications (thrombosis or infection, requiring replacement), and overall survival.
Surgeons within the two vascular surgery divisions (cumulatively, 21 surgeons) at the respective institutions, whose practices include a large proportion of HD access work, performed the procedures. In the early experience at both institutions, IAAVGs were reserved for patients with an urgent need for a durable HD access who lacked appropriate venous anatomy that would warrant the creation of a fistula or placement of an SAVG and simultaneous placement of an interval TDC. Later, some surgeons at each center began to transition toward using IAAVGs as their default conduit for nonautogenous access.
Patency was defined per Society for Vascular Surgery recommended reporting standards and was determined from the time of the index procedure. 8 Follow-up information was obtained through review of inpatient and outpatient records as well as external dialysis center records, when available.
Statistical analysis. Categorical data are described with counts and proportions and continuous data with means, ranges, and standard deviations. Patency rates were analyzed using life-table analysis, and patency rate comparisons were made with a two-group proportion comparison calculator with the P value set as significant at < .05. All analysis was performed using Stata 14 software (StataCorp LP, College Station, Tex).
RESULTS
During the study period, 210 grafts meeting inclusion criteria were implanted. Of these, 148 grafts were SAVGs and 62 were IAAVGs. Most IAAVGs were Acuseal (81%) and 12 were Flixene (28%). Demographics and comorbidities were consistent with U.S. Renal Data System national sample characteristics during this study period (Table I) . The two patient cohorts were largely similar, with >91% of patients in both groups being HD dependent at the time of the index surgery. Most patients had diabetes mellitus, hypertension, and chronic obstructive pulmonary disease. Notably, there was a significantly greater prevalence of prior interventions for or radiographic evidence of central vein outflow obstruction in the IAAVG cohort. The mean number of prior accesses was comparable between the groups; however, there was a significantly larger proportion of patients in the SAVG group with prevalent catheters at the time of graft placement (82% overall; SAVG, 87.6%; IAAVG, 70%; P < .01).
ARTICLE HIGHLIGHTS
The majority of grafts were of a straight, upper arm configuration (Table II) , with no difference between the two groups (55.3% overall; SAVG, 51.8%; IAAVG, 63.8%; P ¼ .12). The majority of upper extremity grafts in each group derived their inflow from the brachial artery (85.3% overall; SAVG, 83.5%; IAAVG, 89.7%; P ¼ .55).
Technical success for access creation was 100%. Eleven (5.2%) patients died within a month of the operation, all of causes thought to be unrelated to the procedure, with no significant difference between the two groups (SAVG, 5.4%; IAAVG, 4.8%; P ¼ .87). There were 15 cases (7.1%) of steal syndrome requiring surgical intervention, with no difference between the two groups (SAVG, 6.8%; IAAVG, 8.1%; P ¼ .74). During follow-up, 26 (16.8%) graft infections were identified, 2 of which were early (within 30 days). Both of these were in the SAVG group. No significant difference in overall infection rates was identified (SAVG, 19.1%; IAAVG, 12%; P ¼ .27). Mean follow-up time was 9.8 6 8.7 months, with no difference between the two groups (SAVG, 10.5 6 8.9 months; IAAVG, 8.0 6 7.8 months; P ¼ .09). Overall survival was 48.1% at 24 months, with no difference between the two groups (SAVG, 51.6%; IAAVG, 37.8%; P ¼ .32; Fig 1) . Seventy-five percent of all grafts were successfully accessed, with comparable rates in each group (SAVG, 73.1%; IAAVG, 80.1%; P ¼ .25). The most common reason for documented nonuse was death before follow-up and lack of confirmation that the graft was used. In others, the graft thrombosed before any documented cannulation, and there was no attempt to salvage it (a new access was placed). There was a significantly shorter median time to first cannulation in the IAAVG group (6 days; interquartile range [IQR], 1-19 days) compared with the SAVG group (31 days; IQR, 26-47 days; P < .01). A large proportion (45%) of IAAVGs were accessed within 72 hours of placement. There were no instances of bleeding or infection attributable to early cannulation (within 10 days of graft placement). With regard to catheter removal, 65% of tunneled catheters were removed, and although no difference was identified with respect to the rate of catheter removal (SAVG, 64.7%; IAAVG, 65.9%; P ¼ .89), the median time until catheter removal was significantly shorter in the IAAVG cohort at 34 days (IQR, 22-50 days) vs 49 days (IQR, 39-67 days) in the SAVG group (P < .01). Catheterrelated complications were significantly lower in the IAAVG group (SAVG, 16.4%; IAAVG, 2.9%; P ¼ .04). The IAAVG cohort required significantly fewer procedures (0.61 6 0.8 per access vs 0.99 6 1.4 per access; P ¼ .03) to achieve the aforementioned comparable patency rates throughout the overall follow-up interval (Tables III and IV) .
DISCUSSION
Our retrospective review of prospectively obtained data serves as one of the largest independent comparisons between SAVGs and IAAVGs. Our study demonstrated a consistent ability to successfully cannulate IAAVGs in the immediate perioperative setting without bleeding complications or infection. Notably, our series finds comparable patency rates between the two graft types, with lower rates of reintervention in the IAAVG cohort. We also found that patients who underwent placement of an IAAVG had the graft cannulated sooner, had earlier catheter removal, and had fewer catheter-related complications.
The first published series of early-cannulation graft implantation were described in the 1980s; however, this technology's entry into extensive clinical practice has only really occurred in the past 10 to 15 years. The first widely used early-cannulation access was the Vectra trilayer graft (C. R. Bard, Murray Hill, NJ). Initial analyses did not identify any additional benefit over standard expanded polytetrafluoroethylene grafts. 9 Subsequent published series demonstrated long-term secondary patency rates comparable to those of brachiobasilic AVFs, but with significantly greater rates of reintervention with the Vectra graft. 9, 10 The Flixene vascular graft has been Food and Drug Administration approved and available for use in the United States for the past 12 years. Per instructions for use, this graft can initially be accessed 72 hours after implantation. The Gore Acuseal vascular graft is the most recent entry into the marketplace of IAAVGs (2013). Like the Vectra and Flixene grafts, the Acuseal is an expanded polytetrafluoroethylene trilayer graft; however, the Acuseal is unique in that its inner lumen is also coated with a layer of covalently bound heparin, and the graft can be accessed within 24 hours of implantation. The Acuseal graft represented the majority of the IAAVGs implanted in our series. Few Acuseal-centric studies exist in the peer-reviewed literature. In those identified, there is significant heterogeneity of results regarding the number of grafts implanted, indications for placement, patency rates, and duration of followup. 11, 12 In the independent European series of 55 Acuseal grafts of Maytham et al, 13 1-year results were notable for 12-month primary patency of 46% and secondary patency of 61%, with 73% of patients being cannulated In comparing the results of our IAAVG cohort with the independent European series, there is congruity; however, compared with the 1-year results of the industry-supported trial of Glickman et al, the primary patency results are comparable, yet there was a significant disparity in the cumulative patency and the total number of reinterventions. The study of Glickman et al claims a cumulative patency rate of 79% but with a larger number of reinterventions (1.6 per access) to achieve this outcome. By comparison, the patients in our series with Acuseal grafts underwent an average of 0.57 6 0.79 procedures per access.
In comparison to recent industry trials, there is a notable discrepancy in our 1-year survival rate. At 12 months, the overall survival rate of 57.9% in our IAAVG cohort is significantly lower than that reported by the Acuseal series of Glickman et al (87.7%) but is comparable to outcomes identified in the U.S. Renal Data System. 15 We attribute this difference to our heterogeneous sample of patients, many of whom were "end-stage dialysis patients" and not just entering a state of end-stage renal disease with new HD dependence. The group from Eastern Virginia Medical School recently reported on their experience with IAAVGs and compared them with their SAVG cases. 16 They reviewed a 14-month experience from 2011 to 2012, with exclusion criteria similar to those of our study, and it is the largest identifiable comparison of SAVGs and IAAVGs outside of our series. Their sample was composed of 78 SAVGs and 44 IAAVGs, with significant heterogeneity of IAAVGs implanted (3 Vectra, 18 Flixene, and 23 Acuseal). They found comparable patency rates between the SAVGs and IAAVGs, with no differences in reintervention rates. The higher rates of reintervention in their IAAVG sample can possibly be attributed to their inclusion of Vectra grafts, with their aforementioned documented higher reintervention rates. The finding of the group from Eastern Virginia Medical School of no reduction in catheter dwell times in the IAAVG group could be related to their earlier period of study, when IAAVGs were less prevalent and targeted postoperative management and early cannulation were not yet pervasive, as was seen in our early experience. The 1-year secondary patency rate in their IAAVG sample (54%) is similar to that found in our series (52.1%).
In 2017, Aitken et al 17 reported on the use of IAAVGs in place of TDCs as a means for urgent HD access. In their randomized trial, IAAVGs were associated with significantly fewer infectious complications compared with TDCs. 15 In their series, they found cost equivalence between the two accesses because the expenses of infectious complications in the TDC arm balanced initial surgical expenditures in the IAAVG arm. 15 Although cost was not an end point in our study, the IAAVG cohort does have a significantly lower rate of infectious complications (12%) compared with historical controls of TDC use, therein supporting the notion that such cost equivalence could also apply in this population of patients. 18, 19 With regard to TDC-related complications, our study's results show that graft type can be associated with decreased rates of untoward catheter-associated events. The meaningfully lower rate of TDC infections and thromboses in our series' IAAVG cohort was not surprising, given the significantly shorter catheter dwell times for those who underwent graft placement with an existing TDC. The reduction in catheter days in the IAAVG cohort is not surprising, but also the potential benefits of reduced catheter days were not fully realized on account of variations in practice patterns and the evolving pervasive use of IAAVGs at our two centers. The approach to assessing catheter removal after graft placement was conservative, using the first date of documented (radiographic or clinical records) evidence of catheter absence as a surrogate date for catheter removal when no specific documentation of catheter removal could be evidenced. This in turn has likely led to an overestimation of catheter dwell time in this series.
Despite 45% of all IAAVGs being accessed within 3 days of placement, an overall median catheter dwell time around 1 month is indicative of a disconnect in the outpatient setting during the postoperative period. Early in this series, because of lack of experience with these novel trilayer grafts, HD unit nurses and their supervising nephrologists were treating these grafts no differently from the SAVGs to which they had become accustomed. Recently, and in large part because of this analysis, a targeted postoperative management plan has been developed that involves communication with the HD unit and early clinic follow-up and TDC removal. This should lead to a dramatic reduction in the catheter dwell times for those with functional IAAVGs. This project does have its limitations, namely, its retrospective nature combined with a heterogeneous sample of patients. Therefore, any comparisons between graft types or generalizations of experience might not necessarily translate to a larger population. Notably, the experience in this series is drawn from a tertiary care setting and might vary from that of community practices with established access creation and management pathways. This project does not directly evaluate the costeffectiveness of the grafts being reviewed, nor does it include an analysis of bovine carotid grafts, which are an alternative to IAAVGs and SAVGs. Further independent, multicenter, randomized prospective study of the performance of IAAVGs and SAVGs would further discern any advantages or pitfalls of this novel technology in the creation of durable HD accesses.
CONCLUSIONS
Real-world experience with immediate-use arteriovenous access grafts is consistent with results from industry-sponsored studies and is not inferior to the results of SAVGs. Compared with SAVGs, IAAVGs offer comparable patency, with reduced interval catheter dwell times as well as reduced rates of catheterassociated complications. Although early cannulation of immediate-access grafts can be successfully placed in a wide variety of patients, without any increased risk of ischemic steal, bleeding events, or infection, prolonged catheter dwell times can still persist in actual practice. Further study of focused efforts toward establishing protocols for close follow-up, early cannulation, and subsequent catheter removal in those undergoing IAAVG implantation is warranted. 
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